Berinert denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BlueCross BlueShield May Deny Berinert as Not Medically Necessary

Berinert is a plasma-derived C1 esterase inhibitor (C1-INH) concentrate used to treat acute hereditary angioedema (HAE) attacks. A medical-necessity denial from BCBS typically means the documentation submitted with the prior-authorization request did not clearly establish that the patient meets the clinical criteria in BCBS's Medical Policy for Berinert — most commonly because the HAE diagnosis was not confirmed with the required genetic or laboratory evidence, because attack frequency or severity was not adequately documented, or because the treating prescriber's notes did not address the specific clinical criteria the policy requires. Medical-necessity denials for Berinert are highly appealable when the treating specialist's documentation is thorough and policy-responsive.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal appeal and, if that is upheld, independent external review through an accredited IRO. Submit the external-review request within four months of the final adverse determination. Because HAE attacks — particularly laryngeal attacks — can be life-threatening, expedited review (72-hour decision) is appropriate and should be requested in any case involving recent severe attacks or a patient at risk for airway compromise.

## The Appeal Process

1. Obtain the denial letter and the BCBS Medical/Coverage Policy for Berinert; identify each criterion that was found unmet. 2. Work with the treating HAE specialist to prepare documentation that addresses each unmet criterion directly. 3. File a Level 1 internal appeal with the complete, policy-responsive documentation package. 4. If upheld, proceed to Level 2 and then external IRO review. 5. Request an expedited internal appeal if there is any clinical urgency.

## Documentation to Gather

• HAE diagnosis confirmation: Genetic testing results or repeated laboratory measurements of C1-INH antigenic level and functional activity, and/or C4 level, interpreted by the treating specialist — confirming the specific type of HAE as required by the BCBS policy.
• Attack history: A detailed attack log or specialist summary documenting attack frequency, severity, duration, anatomical location (especially abdominal and laryngeal attacks), and any hospitalizations or emergency visits related to HAE, covering a clinically meaningful lookback period.
• Prior treatment history: Records of any other HAE acute treatments previously used, with outcomes, establishing why Berinert is appropriate and necessary.
• Clinical severity assessment: A specialist note characterizing the patient's disease burden — attack impact on daily function, work, school — that contextualizes the medical necessity.
• Prescriber medical-necessity letter: A detailed, policy-responsive letter from the treating allergist, immunologist, or HAE specialist that cites each BCBS criterion explicitly, provides the chart evidence satisfying it, and references the applicable HAEA guideline recommendation for acute HAE treatment.

## Criteria-Mapping Structure

Obtain the BCBS Medical Policy for Berinert and build a point-by-point response:

| BCBS Medical Necessity Criterion | Satisfying Chart Evidence | |---|---| | Confirmed HAE diagnosis (type specified in policy) | Lab/genetic results with specialist interpretation | | Attack frequency / severity threshold (per policy) | Attack log with specialist summary | | Prescriber specialty requirement (if any) | Treating specialist credentials | | Absence of adequate response to alternative agents (if required) | Prior-treatment records with outcomes | | Any additional policy criterion | Corresponding chart note or test result |

A criterion-by-criterion response — rather than a general narrative — is the most effective structure for overturning a medical-necessity denial.